Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

NCT02867813 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
5035
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen